WallStSmart

Novo Nordisk A/S (NVO)vsOtter Tail Corporation (OTTR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 24852% more annual revenue ($327.80B vs $1.31B). NVO leads profitability with a 37.2% profit margin vs 21.3%. OTTR appears more attractively valued with a PEG of 1.81. NVO earns a higher WallStSmart Score of 74/100 (B).

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13

OTTR

Strong Buy

67

out of 100

Grade: B-

Growth: 4.0Profit: 7.5Value: 4.7Quality: 6.3
Piotroski: 2/9Altman Z: 1.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NVO.

OTTRSignificantly Overvalued (-60.8%)

Margin of Safety

-60.8%

Fair Value

$53.45

Current Price

$88.03

$34.58 premium

UndervaluedFair: $53.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

OTTR4 strengths · Avg: 8.3/10
Profit MarginProfitability
21.3%9/10

Keeps 21 of every $100 in revenue as profit

P/E RatioValuation
13.2x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Operating MarginProfitability
24.7%8/10

Strong operational efficiency at 24.7%

Areas to Watch

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

OTTR4 concerns · Avg: 3.8/10
PEG RatioValuation
1.814/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

Altman Z-ScoreHealth
1.674/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bull Case : OTTR

The strongest argument for OTTR centers on Profit Margin, P/E Ratio, Price/Book. Profitability is solid with margins at 21.3% and operating margin at 24.7%.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Bear Case : OTTR

The primary concerns for OTTR are PEG Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

NVO profiles as a growth stock while OTTR is a value play — different risk/reward profiles.

OTTR carries more volatility with a beta of 0.47 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (74/100 vs 67/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Otter Tail Corporation

INDUSTRIALS · CONGLOMERATES · USA

Otter Tail Corporation is engaged in electrical service, manufacturing and plastic piping businesses in the United States. The company is headquartered in Fergus Falls, Minnesota.

Want to dig deeper into these stocks?